SUPPORTING INFORMATION

Evaluation of the clinical cardiac safety of pemigatinib, a fibroblast growth factor receptor inhibitor, in participants with advanced malignancies

Xiaohua Gong | Tao Ji | Xiang Liu | Xuejun Chen | Swamy Yeleswaram

Incyte Research Institute, Incyte Corporation, Wilmington, DE 19803, USA

Correspondence: Xiaohua Gong, PhD, Incyte Research Institute. Wilmington, DE 19803, USA. E-mail: xgong@incyte.com.
**TABLE S1**  Categorical analysis of absolute or change from baseline QTcF

| Category | 1/2/4/6 mg QD | 9 mg QD | 13.5 mg QD | 20 mg QD | Total |
|----------|---------------|---------|------------|----------|-------|
| Participant | QTcF total, N | 7 | 21 | 67 | 18 | 113 |
| | QTcF >450 and ≤480 ms, n (%) | 0 | 4 (19.0) | 11 (16.4) | 3 (16.7) | 18 (15.9) |
| | QTcF >480 and ≤500 ms, n (%) | 0 | 0 | 1 (1.5) | 1 (5.6) | 2 (1.8) |
| | QTcF >500 ms, n (%) | 0 | 0 | 0 | 0 | 0 |
| Time point | QTcF total, N | 47 | 129 | 387 | 119 | 688 |
| | QTcF >450 and ≤480 ms, n (%) | 0 | 11 (8.5) | 28 (7.2) | 8 (6.7) | 47 (6.8) |
| | QTcF >480 and ≤500 ms, n (%) | 0 | 0 | 1 (0.3) | 1 (0.8) | 2 (0.3) |
| | QTcF >500 ms, n (%) | 0 | 0 | 0 | 0 | 0 |
| Participant | Total, N | 7 | 21 | 67 | 18 | 113 |
| | ΔQTcF >30 and ≤60 ms, n (%) | 0 | 2 (9.5) | 6 (9.0) | 1 (5.6) | 9 (8.0) |
| | ΔQTcF >60 ms, n (%) | 0 | 0 | 0 | 0 | 0 |
| Time point | Total | 40 | 107 | 316 | 101 | 564 |
| | ΔQTcF >30 and ≤60 ms, n (%) | 0 | 3 (2.8) | 6 (1.9) | 2 (2.0) | 11 (2.0) |
| | ΔQTcF >60 ms, n (%) | 0 | 0 | 0 | 0 | 0 |

QD = once daily; QTcF = QT interval corrected for heart rate by Fridericia’s method.
FIGURE S1 Change from baseline across nominal stage/time points for ECG parameters. Data shown are least squares mean ΔQTcF (A), ΔHR (B), ΔPR (C) and ΔQRS (D); bars represent 90% confidence intervals. Δ = change from baseline; C = cycle; D = day; ECG = electrocardiogram; Hr = hour; HR = heart rate; QD = once daily; QTcF = QT interval corrected for heart rate by Fridericia’s method; SS = steady state.
FIGURE S2 Model-predicted ΔQTcF (mean and 90% confidence interval) for day 1 of the first cycle overlaid with observed mean ΔQTcF (mean and 90% confidence interval) across deciles of pemigatinib plasma concentrations. ΔQTcF = change from baseline QT interval corrected for heart rate by Fridericia’s method.